抗骨质疏松药物对脊柱融合手术效果的影响  

Research progress on the impact of anti-osteoporosis drugs on the efficacy of spinal fusion surgery

作　　者：王翔鹤 聂聪 王洪立 姜建元 WANG Xianghe;NIE Cong;WANG Hongli;JIANG Jianyuan(Department of Orthopaedics,Huashan Hospital,Fudan University,Spine Surgery Center,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院骨科复旦大学脊柱外科中心,上海200040

出　　处：《中华骨与关节外科杂志》2024年第12期1137-1143,共7页Chinese Journal of Bone and Joint Surgery

基　　金：复旦大学附属华山医院“优秀人才培养奖励计划”(19-02-04)。

摘　　要：骨质疏松症是一种以骨量丢失、骨强度下降为特征的代谢性骨病,其严重影响了脊柱融合手术的预后。抗骨质疏松药物通过调控骨重建过程,治疗骨质疏松、促进脊柱融合,并减少并发症,已成为重要的临床干预手段。本文就不同种类的抗骨质疏松药物对脊柱融合过程的影响、机制及研究进展进行综述,对目前临床用药的推荐方案与用药时机进行归纳,并对未来研究方向进行展望,旨在为合并骨质疏松症的脊柱融合手术患者围手术期用药提供参考。Osteoporosis is a metabolic bone disease characterized by decreased bone mass and bone strength,significantly affecting the prognosis of spinal fusion surgery.Anti-osteoporosis drugs,by regulating the bone remodeling process,have become an important clinical intervention for treating osteoporosis,promoting spinal fusion,and reducing complications.This review examines the effects,mechanisms,and research progress of different types of anti-osteoporosis drugs on the spinal fusion process.It also summarizes current clinical recommendations for drug selection and timing of administration,and explores future research directions,aiming to provide guidance on the use of these drugs for patients with osteoporosis during the perioperative period of spinal fusion surgery to improve clinical outcomes.

关 键 词：抗骨质疏松药物 脊柱融合 骨质疏松症 骨重建 

分 类 号：R681.5[医药卫生—骨科学]